ORIGINAL ARTICLE

Profiling of circulating chromosome 21-encoded microRNAs, miR-155, and let-7c, in down syndrome

Jesús Manuel Pérez-Villarreal1,2,3 | Katia Aviña-Padilla4,5 | Evangelina Beltrán-López6 | Alma Marlene Guadrón-Llanos7 | Esther López-Bayghen8 | Javier Magaña-Gómez2,3 | Marco Antonio Meraz-Ríos9 | Alfredo Varela-Echavarria4 | Carla Angulo-Rojo1,10

1Laboratorio de Neurociencias, Centro de Investigación Aplicada a la Salud Pública (CIASaP), Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán, Mexico
2Maestría en Ciencias Biomédicas, Facultad de Ciencias Químico-Biológicas, Universidad Autónoma de Sinaloa, Culiacán, Mexico
3Laboratorio de Nutrición Molecular, Escuela de Nutrición y Gastronomía, Universidad Autónoma de Sinaloa, Culiacán, Mexico
4Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, Mexico
5Laboratorio de Bioinformática y de Redes Complejas, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IRAPUATO), Mexico
6Laboratorio Edificio Central, Facultad de Ciencias Químico-Biológicas, Universidad Autónoma de Sinaloa, Culiacán, Mexico
7Laboratorio de Diabetes y comorbilidades, Centro de Investigación Aplicada a la Salud Pública (CIASaP), Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán, Mexico
8Departamento de Toxcológia, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), México City, Mexico
9Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), México City, Mexico
10Centro de Investigación y Docencia en Ciencias de la Salud (CIDOCS), Universidad Autónoma de Sinaloa, Culiacán, Mexico

Abstract

Background: Down syndrome (DS) is the most common chromosomal survival aneuploidy. The increase in DS life expectancy further heightens the risk of dementia, principally early-onset Alzheimer’s disease (AD). AD risk in DS is higher, considering that this population may also develop metabolic diseases such as obesity, dyslipidemias, and diabetes mellitus. The extra genetic material that characterizes DS causes an imbalance in the genetic dosage, including over-expression of AD’s key pathophysiological molecules and the gene expression regulators, the microRNAs (miRNAs). Two miRNAs, chromosome 21-encoded, miR-155, and let-7c, are associated with cognitive impairment and dementia in adults; but, expression dynamics and relationship with clinical variables during the DS’s lifespan had remained hitherto unexplored.

Methods: The anthropometric, clinical, biochemical, and profile expression of circulating miR-155 and let-7c were analyzed in a population of 52 control and 50

Correspondence
Carla Angulo-Rojo, Laboratorio de Neurociencias, Centro de Investigación Aplicada a la Salud Pública (CIASaP), Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, México.
Email: carla.angulo@uas.edu.mx

Funding information
Carla Angulo-Rojo and Javier Magaña-Gómez received financial support from Universidad Autónoma de Sinaloa (PROFAPI2014/015 and PROFAPI2015/015). Jesús Manuel Pérez-Villarreal received a Master fellowship from CONACyT (CVU785590). Katia Aviña-Padilla received a postdoctoral fellowship from DGAPA-UNAM and currently from CONACyT (CVU227919).
1 | INTRODUCTION

Down syndrome (DS), or trisomy 21, is the most common survivable chromosomal aneuploidy, occurring at a rate that ranges between 6 and 13 in 10,000 births (de Graaf et al., 2017; Sierra Romero et al., 2014). The prevalence of DS increased in recent decades as the life expectancy of people with this condition has expanded to 60 years and beyond (Saghazadeh et al., 2017), leading to a primarily understudied population in the aging process. Furthermore, adults with DS are at higher risk for early onset Alzheimer’s disease (AD), the most common form of dementia (Antonarakis et al., 2004). It was recently reported that adults aged 40–54 years have a 40% probability of an incident dementia claim, which increases to 67% for those 55 years and older (Rubenstein et al., 2020). Moreover, DS individuals have an increased risk of overweight, obesity, and dyslipidemias, which are also risk factors for AD (Bertapelli et al., 2016). Hence, there is a critical need to identify biomarkers to track neuropathology and cognitive decline in DS people to prevent it and provide proper medical care to this population.

Most of the features of DS relate to over-expression of the genes located on chromosome 21, particularly those of the Down Syndrome Critical Region (DSCR), leading to imbalanced interactions with other disomic genes (Asim et al., 2015). In DS individuals, the increased risk of early-onset Alzheimer’s disease is related to the trisomic dosage of the genes for amyloid precursor protein (APP, OMIM #104760) and β secretase 2 (BACE2, OMIM #605668), essential proteins for amyloid-beta (Aβ) peptide production (Ballard et al., 2016). Deposits in the brain of Aβ peptide, along with neurofibrillary tangles caused by hyperphosphorylation and accumulation of Tau protein, are the pathological hallmarks of AD (Scheltens et al., 2016).

Furthermore, other genes for early molecular players in the pathophysiology of DS and AD such as microRNAs (miRNAs), are also located on chromosome 21 (Antonarakis, 2017). Their expression during lifespan, however, remains thus far uncharacterized.

miRNAs are small non-coding strands of RNA (18–25 nucleotides), which regulate post-transcriptionally almost 60% of all gene expression via inhibition of translation or direct mRNA target degradation (Friedman et al., 2009). These small regulatory RNAs often have tissue-specific expression, are detectable in peripheral blood, and may act as endocrine effectors on target cells. Hence, they have been proposed as circulating biomarkers for neurodegeneration.

Human chromosome 21 has more than 400 genes, including five miRNAs (miR-99a, let-7c, miR-125b-2, miR-155, and miR-802) whose expression leads to haploinsufficiency for their mRNA target (Elton et al., 2010). miRDB database analysis (http://mirdb.org/index.html) (Chen & Wang, 2019) predicted that miR-99a is a potential interactor of 47 mRNA targets, let-7c of 990, miR-125b-2 of 585, miR-155 of 701, and miR-802 of 631. It follows then that dysregulation of these miRNAs may play a role in the cognitive dysfunction and early-onset AD in individuals with DS.

Among those miRNAs, we focused on let-7c and miR-155, which are critically related to neurodegeneration and play a crucial role in DS pathogenesis of dementia (McGowan et al., 2018; Tili et al., 2018). The extra copy of miR-155 may contribute to neuroinflammation in AD related to NF-kB signaling, T cell activation, and infiltration in the hippocampal brain parenchyma (Tili et al., 2018). Moreover, miR-155 is co-expressed with hyperphosphorylated Tau (Ballard et al., 2016; Tili et al., 2018), and over-expression of let-7c leads to impaired neuronal morphologic development, synapse formation, and synaptic dysfunction.
strength, as well as a marked reduction of neuronal excitability (Chen et al., 2018; McGowan et al., 2018). In addition to the known interactors of let-7c and miR-155, there are unexplored mRNA targets involved in processes linked both to DS and AD pathology. For example, DS people are at risk of dyslipidemia characterized by high levels of triglycerides and low-density lipoprotein cholesterol (LDL-Col) and low levels of high-density lipoprotein Cholesterol (HDL-Col) (Adelekan et al., 2012; Buonuomo et al., 2016; de la Piedra et al., 2017; Tenneti et al., 2017). In turn, dyslipidemia in these individuals increases the risk of AD, as HDL-Col is required for the Aβ peptide clearance (Kuo et al., 1998; Robert et al., 2017).

Therefore, in the present work, we focused on profiling the expression of circulating miR-155 and let-7c miRNAs in the young and adult DS population and exploring its possible correlations with AD risk factors present in DS, such as the lipid profile.

2 | MATERIALS AND METHODS

2.1 | Study design

A cross-sectional study was performed with 50 participants with DS and 52 healthy controls. Individuals were selected at Down Syndrome Health Fairs organized by the Autonomous University of Sinaloa.

DS individuals and controls were each grouped in 20-year-old or younger (Group A) and 21-year-old or older (Group B), according to the growth standards for children with DS by the Disease Control and Prevention Center (CDC).

2.2 | Patients

The study’s inclusion criteria were age over 8 years and a DS diagnosis by clinical and genetic criteria. Sex and age-matched control participants were used as a reference. Exclusion criteria were the presence of congenital heart disease not treated with surgery, severe sensory impairment, leukemia, and diagnosis of diabetes mellitus or metabolic syndrome.

2.3 | Anthropometric measurements

Anthropometric measurements were carried out following the procedures of the International Society for the Advancement of Kinanthropometry (ISAK) during patient examinations. Bodyweight was measured on subjects wearing light clothes using an electronic bascule (Tanita HS-302) and height using a stadiometer (SECA 213). Body mass index (BMI) was calculated, and individuals were classified according to the World Health Organization’s BMI/Age tables (WHO).

2.4 | Biochemical analysis

After an overnight fast, blood samples were obtained from the antecubital vein and collected into two non-additive tubes. They were incubated for 30 min at room temperature and spun at 3,000g at 4°C for 10 min. Serum samples were collected and stored at −80°C. Serum lipids (total cholesterol and HDL-cholesterol), triglycerides, and plasma glucose were measured using commercial enzymatic kits (HUMAN Diagnostics Worldwide; Wiesbaden, Germany). LDL-cholesterol was calculated using a modified Friedewald equation (Friedewald et al., 1972). For the classification of biochemical parameters, we used the cut-off points of the International Diabetes Federation (IDF) and the National Cholesterol Education Program (NCEP) for children, adolescents, and adults (NIH and NHLBI, 2001; Zimmet et al., 2007). The cutoff point is ≥200 mg/dl for total cholesterol, ≥130 mg/dl for LDL-cholesterol, ≥150 mg/dl for triglycerides, and ≥100 mg/dl for glucose, applicable for all ages. In the case of HDL-cholesterol <40 mg/dl (8–16 years old, male/female) and <40/50 mg/dl (people >16 years old, male/female).

2.5 | RNA isolation

According to the manufacturer’s protocol; total miRNA purification from 200μl of serum was performed with the miRNeasy-serum/plasma extraction kit (Qiagen, Hilden, Germany). Samples were eluted with RNase-free water for subsequent cDNA synthesis and stored at −80°C.

2.6 | Reverse transcription (RT) and real-time PCR

Total RNA was reverse transcribed using a miScript II RT Kit (Qiagen) in a StepOne Plus (Thermo Fisher Scientific) according to the manufacturer’s protocol and using equal volumes for all samples.

Quantification of let-7c (cat. no. 00003129) and miR-155 (cat. no. 00031486) mature miRNAs were determined using the miScript SYBR Green PCR kit (Qiagen) and SNORD68 (cat. no. 00033712) as normalizer (Abd-El-Fattah et al., 2013; Kumar et al., 2018). PCR reactions were each performed in a final volume of 15μl in the StepOne Plus thermocycler (Applied Biosystems). The Melting
Curve was performed to observe the specificity of reactions. Relative quantification was obtained using the Pfaffl method (Pfaffl, 2001), which describes the use of reaction efficiencies obtained using LinReg PCR software (Ruijter et al., 2009).

2.7 | In silico prediction of miRNAs and their target genes

For predicting miR-155 and let-7c gene targets, miRDB (http://www.mirdb.org) public database was used (Agarwal et al., 2015; Chen & Wang, 2019). To determine the biological processes under each miRNA regulation, we performed network enrichment analysis using Metascape (Zhou et al., 2019) (http://metascape.org/). Then, we selected GO terms in miR155 targets related to lipid metabolism. Finally, we used the Meta-analysis workflow to compare miR155 and let-7c targets and to identify unique and shared biological pathways in which they are involved.

2.8 | Statistical analysis

Statistical tests were performed using SPSS v.22. Data were examined for normality based on skewness and kurtosis before analysis. Descriptive statistics of clinical characteristics between groups were represented as means ± standard deviation. Mann–Whitney U and Student’s t-test were used to examine the statistical difference in clinical parameters between healthy controls subjects and DS patients. ANOVA Kruskal-Wallis test for differences between groups with respect to miRNA expression was assessed. Spearman correlation coefficients determined correlations between fold changes of miRNA levels and changes in biochemical characteristics. Statistical significance was set at \( p < 0.05 \).

3 | RESULTS

3.1 | Anthropometry and biochemical parameters

The circulating profile expression of chromosome 21-encoded miRNAs miR-155 and let-7c may be impacted by risk factors as clinical variables related to metabolism. To better characterize these variables, we analyzed anthropometry and biochemical parameters in control and DS populations. A total of 50 individuals with Down syndrome and 52 healthy controls from 8 to 52 years of age were characterized and divided into two groups: A (A Control and A DS, aged \( \leq 20 \) years) and B (B Control and B DS, aged \( \geq 21 \) years). All individuals were matched by sex and age. The mean age was 10.9 ± 2.4 and 11.3 ± 2.7 years for A Control and A DS groups, respectively; and 28.3 ± 11 and 28.5 ± 11 years for B Control and B DS groups (Table 1), respectively, with no significant difference between them, which indicates homogeneity of age-divided groups. For bodyweight, there was no significant difference between A groups (Control 41.4 ± 12.5 and DS 37.9 ± 13.2 kg) and B groups (Control 63.3 ± 10.3 and DS 64.3 ± 12.7 kg, \( p = 0.001 \)), while no difference was observed between A groups (Table 1).

| Clinical characteristics | Control A | DS A | p-value | Control B | DS B | p-value |
|--------------------------|-----------|------|---------|-----------|------|---------|
| Age (years)              | 10.9 ± 2.4| 11.3 ± 2.7 | NS      | 28.3 ± 11 | 28.5 ± 11 | NS      |
| Bodyweight (kg)          | 41.4 ± 12.5| 37.9 ± 13.2 | NS      | 63.3 ± 10.3| 64.3 ± 12.7| NS      |
| Height (m)               | 1.45 ± 0.11| 1.3 ± 0.12 | 0.0001  | 1.6 ± 0.07 | 1.5 ± 0.08 | 0.0001  |
| BMI (kg/m²)              | 19.2 ± 3.3 | 20.5 ± 4.3 | NS      | 22.9 ± 2.6 | 28.8 ± 6.0 | 0.006   |
| Glucose (mg/dl)          | 86.4 ± 11.1| 87.4 ± 10.4 | NS      | 91.08 ± 5.1| 91 ± 13.6 | NS      |
| Cholesterol (mg/dl)      | 118.7 ± 30.2| 181.2 ± 44.6 | 0.0001  | 157.4 ± 60.6| 171.7 ± 54.2| NS      |
| HDL (mg/dl)              | 56.8 ± 15.4| 46.7 ± 13.17| 0.003   | 68.8 ± 13.2| 42.5 ± 9.1 | 0.0001  |
| Triglycerides (mg/dl)    | 75.6 ± 43.3| 139.1 ± 44.5 | 0.0001  | 80.3 ± 24.5| 152.7 ± 83.5| 0.011   |
| LDL (mg/dl)              | 109.6 ± 43.1| 106.4 ± 37.6 | NS      | 72.8 ± 55.1| 115 ± 28.07| 0.029   |

Note: Data are presented as mean ± SD.

Abbreviations: BMI, body mass index; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; NS, non-significative.
Altogether, these results indicate that the risk of overweight in DS individuals is higher at older stages, in accordance with previous reports (Basil et al., 2016; Bertapelli et al., 2016).

Biochemical analysis revealed a significant difference between Control and DS A groups in total cholesterol (118.7 ± 30.2 and 81.2 ± 44.65 mg/dl, \( p = 0.0001 \)), HDL (56.82 ± 15.4 and 46.7 ± 13.17 mg/dl, \( p = 0.003 \)) and triglycerides (75.65 ± 43.33 and 139.1 ± 44.53 mg/dl, \( p = 0.0001 \)), but not for LDL and glucose levels (Table 1). Similarly, for B groups we observed differences in HDL (68.8 ± 13.2 and 42.5 ± 9.1 mg/dl, \( p = 0.0001 \)), triglycerides (80.3 ± 24.5 and 152.7 ± 83.5 mg/dl, \( p = 0.011 \)) and LDL (72.8 ± 55.15 and 115 ± 28.07 mg/dl, \( p = 0.029 \)), but not for total cholesterol and glucose (Table 1). Overall, these results show alterations in lipid metabolism parameters due to the genetic background of DS.

### 3.2 Serum miRNAs expression

Analysis by qRT-PCR of let-7c expression revealed a 2.2-fold increase in DS relative to the control group (Figure 1a) for the overall population. Moreover, when analyzed according to age, we observed a similar over-expression of let-7c in DS groups compared to their respective control groups in the young and adult populations (DS A: 2.3-fold and DS B: 1.8-fold) (Figure 1a). Nevertheless, some DS overexpresses miR-155, no significant differences were detected for miR-155 in both analyses (Figure 1b).

We then analyzed differences in the miRNA expression levels classifying the DS population according to normal or altered clinical parameters related to metabolism, as described in materials and methods. When focusing on lipid parameter alterations, we did not find differences in expression levels of miR-155 between normal or altered lipid parameter subgroups (Table 2). Interestingly, the most remarkable change detected in the expression of let-7c was among the Low-HDL DS population (2.9-fold) and this effect was lower in the normal-HDL DS group (1.7-fold) (Table 2).

### 3.3 Correlation between miRNA expression and biochemical parameters

Dyslipidemias are a risk factor for chronic complications in DS and may increase the risk of Alzheimer’s disease. Since lipid concentrations have been linked to cognitive impairment, patients’ biochemical parameters were
correlated with expression values of miRNAs let-7c and miR-155 (Table 3). We did not find a correlation for let-7c levels with any lipid or glucose parameter (Table 3). However, we observed a negative correlation between the HDL levels and the increase in the expression of miR-155 ($p = 0.004$, $r = −0.395$) (Table 3). Interestingly, an overall landscape showed that DS individuals have let-7c miRNA expression up-regulated, especially in individuals with low-HDL (Tables 2 and 3). Meanwhile, miR-155 levels appear up-regulated only when HDL levels are far below normal (Tables 2 and 3). Hence, the results suggest that only miR-155 mRNA targets relate to the regulation of lipid metabolism.

### 3.4 Functional enrichment of gene targets of miR-155 and let-7c

To gain insight into the role of miR-155 and let-7c targets that could be differentially affected in DS comorbidities, we performed an in-silico analysis to find enriched biological pathways. miR-155 and let-7c targets were determined using the miRDB (http://www.mirdb.org) public database. Clustering networks of the top 20 enriched GO: BP (Gene Ontology: Biological Processes) terms for miR-155 and let-7c targets are shown in Figure 2. In-silico prediction analysis showed that miR-155 has 701 mRNA targets, while let-7c could be regulating 990 genes. Comparative analysis of their targets showed that only 52 genes could be regulated by both miRNAs (Figure 3 and Figure S1). Despite the discrepancy in genetic regulation, both miRNAs are linked at the biological pathway level (Figure S1). It is noteworthy that enrichment analysis of biological processes revealed that the highest $p$-value enriched GO: BP terms are unique pathways for each miRNA (Figures 2 and 3).

Bioinformatic analyses of let-7c gene targets revealed enrichment of the signaling pathways associated with diseases, particularly to type 2 diabetes, such as the AGE/RAGE pathway and the carbohydrate derivate biosynthetic process (Figure 2a). A possible mechanism of let-7c genetic regulation is the signaling cascade events of the IGF-1/IGF-1R pathway, which induces the phosphorylation and inhibition of forkhead (FoxO) transcription factors. The FoxO signaling pathway, highly enriched among let-7c targets, is involved in the regulation of both survival and apoptotic genes by inducing the synthesis of the ligand of the apoptosis stimulating fragment (FasL) and the death mediator that interacts with BcL-2 (Bim) (Figure 2a). Overall, these results suggest a function for let-7c in cell survival and carbohydrate metabolism linked to the molecular etiology of neurodevelopmental disorders, such as DS.

Among the miR-155 unique gene targets, we observed a high enrichment for a group of homophilic
FIGURE 2  Networks of enriched ontology clusters for let-7c (a) and miR-155 (b) miRNAs regulated targets. GO: BP, gene ontology: biological processes terms
adhesion proteins via plasma membrane adhesion composed mostly of clustered alpha protocadherins (Pcdhs) and other non-clustered members (Figure 2b). Also, miR-155 is related to inflammatory pathways such as interleukin signaling and oncogenic signaling. Due to among the top 20 enriched GO: BP terms for miR-155, no highly enriched terms associated with lipid metabolism were found, we performed further analysis for lipid-linked biological processes from all the significantly enriched terms. We identified 60 miR155-target genes involved in those lipid metabolism processes, with enrichment in GO: BP associated with lipid metabolism processes, with enrichment in GO: BP associated with cellular response to lipid, inositol lipid-mediated signaling, long-chain fatty acid import, positive regulation of lipid localization, and fat cell differentiation (−log10 ranking from −3.499 to −2.058) (Table 4 and Figure S2). Furthermore, miR-155 mRNAs targets are implicated in the Reactome pathway R-HSA-400206: Regulation of lipid metabolism by PPAR alpha (−log10=−2.51) (Table 4). The latest deep bioinformatics analysis applied to let-7c did not find mRNA targets related to lipid metabolism (data not shown).

4 | DISCUSSION

Worldwide, the adult population with Down’s syndrome is growing, and there is a lack of clinical guidelines for these patients’ care (Tsou et al., 2020). DS populations carry a higher risk for chronic degenerative diseases such as cardiovascular illnesses, diabetes mellitus, dyslipidemia, metabolic syndrome, and neurodegenerative diseases such as Alzheimer’s dementia (Tsou et al., 2020). Therefore, to improve the preventive and therapeutic approach to DS comorbidities, it is necessary to understand them from their molecular level to their clinical features. The small non-coding miRNAs play roles at early pathological stages and mobilize through the bloodstream, making their study feasible by non-invasive methods (Weber et al., 2010). Therefore, the present study analyzed the profile expression of pathological circulating chromosome 21-encoded miR-155 and let-7c miRNAs in DS and euploid populations. These miRNAs have been previously implicated in neurodegeneration and are also linked to dyslipidemias and early-stage development of Alzheimer’s pathogenesis (McGowan et al., 2018; Tili et al., 2018).

First, we characterized clinical features related to metabolism in DS and control populations, as this aneuploidy may affect the profile expression of miRNAs when compared to a euploid control. As expected, we found an increased height for the control group, similar to reported short stature as a typical feature in DS, and growth velocity markedly reduced, mainly between the ages ranging from 6 months to 3 years (Anneren et al., 1993). Moreover, we also observed that BMI was larger in DS than the control in the older group analyzed (B groups), while no differences were observed between the younger groups (A control and A DS groups). Previous studies in children and adolescents revealed that children with DS have a healthy BMI, which may be due to parental control in their diet (Melville et al., 2005). However, during
| GO Category | Parental GO | Description | Genes | LogP | Enrichment | Z-score |
|-------------|-------------|-------------|-------|-------|------------|---------|
| GO biological processes | | | | | | |
| GO:0045444  | GO Biological Processes | 19_GO:0032502 developmental process | Fat cell differentiation | ARNTL, CEBPB, GATA3, HNRNPU, ENPP1, RORA, RREB1, SORT1, TCF7L2, WNT5A, PIAS1, SOCS1, MAFB, TRIM32, ZADH2, PTPRQ | -3.499 | 2.715 | 4.234 |
| GO:0045599  | GO Biological Processes | 19_GO:0048519 negative regulation of biological process | Negative regulation of fat cell differentiation | ARNTL, GATA3, ENPP1, RORA, SORT1, WNT5A, ZADH2 | -3.476 | 5.289 | 5.002 |
| GO:0045598  | GO Biological Processes | 19_GO:0032502 developmental process | Regulation of fat cell differentiation | ARNTL, CEBPB, GATA3, HNRNPU, ENPP1, RORA, RREB1, SORT1, WNT5A, ZADH2, PTPRQ | -3.019 | 3.080 | 3.991 |
| GO:0071396  | GO Biological Processes | 19_GO:0050896 response to stimulus | Cellular response to lipid | ABL2, ARNTL, ARRB2, CD36, CEBPB, ABC2, DEFA5, HNRNPU, IRF8, NR3C2, MYB, NXX3-1, PDK4, PTN, RELA, RORA, SMARCA4, SOX9, SOX10, WNT5A, PIAS2, PDCD4, CD274, STRN3, KDM3A, IL36G, AICDA, CREBRE | -2.99 | 1.900 | 3.538 |
| GO:0048017  | GO Biological Processes | 19_GO:0023052 signaling | Inositol lipid-mediated signaling | CA8, CBL, ENTPD5, CSF1R, GATA3, NXX3-1, RPS6KB1, SOX9, BTN2A2, FBXL2, KBTBD2, PLEKHA1, DIPK2A | -2.864 | 2.656 | 3.723 |
| GO:0044539  | GO Biological Processes | 19_GO:0051179 localization | Long-chain fatty acid import | CD36, RPS6KB1, SPX | -2.787 | 2.014 | 5.574 |
| GO:1905954  | GO Biological Processes | 19_GO:0048518 positive regulation of biological process | Positive regulation of lipid localization | CD36, MYB, NXX3-1, LRAT, IKBKE, EHD1, LDLRAP1 | -2.058 | 3.014 | 3.113 |
| Reactome gene sets | | | | | | |
| R-HSA-400206 | Reactome Gene Sets | NA | Regulation of lipid metabolism by PPARalpha | ARNTL, CD36, RORA, SP1, MED21, GLIPR1, MED13L, AHR, CHD9 | -2.518 | 3.028 | 3.549 |
adulthood, DS individuals have greater independence for choosing their food, which tends to have a higher caloric content (Grammatikopoulou et al., 2008). Risk factors associated with the development of obesity such as a decrease in basal metabolism, are also present in DS (Allison et al., 1995; Luke et al., 1994). Moreover, individuals with DS have muscular hypotonia, a phenotype characterized by difficulty in performing activities that involve physical attrition, contributing to a sedentary lifestyle, and, consequently, to weight gain (Korenberg et al., 1994; Shahabi et al., 2017).

In addition to obesity and dyslipidemias, alterations in miRNA expression could synergize the risk for impaired cognition and have a possible link with AD’s early age onset. The miRNAs let-7c and miR-155, both present on chromosome 21, were selected for their importance in phenotype variability generating haploinsufficiency of target genes and their possible relation with the development of Alzheimer’s disease in patients with DS, even at early ages.

Notably, our profiling results highlight a 2.2-fold expression increase of circulating let-7c expression in the DS group compared to the euploid population. Following Tili et al. (Tili et al., 2018), who recently reported an upregulation of let-7c in the DS population using samples from brain tissues (n = 6) and observed a high heterogeneity in the cortex (n = 4) ranging from 1.63 to 16.48-fold change (n = 3). In a separate study, Xu et al. (2013) also found let-7c overexpression (1.5-fold-change, n = 6) in DS lymphocytes. We consider that our study also contributes to a better characterization of the circulating let-7c that reaches all tissues, including the brain, and its pathophysiological effects may synergize to the DS comorbidities, such as dementia (Figure 4) (Tili et al., 2018; Xu et al., 2013). Based on the results obtained and the previous evidence, to better understand the role that let-7c and miR-155 play in the molecular neurodegeneration puzzle, we constructed the drawing shown in Figure 4, reference hereafter thorough discussion.

It is well known that let-7c is involved in mechanisms related to neurological alterations as an activator of TLR7, in both immune cells and neurons, damaging the CNS through the production of proinflammatory molecules such as the tumor necrosis factor α (TNFα). Moreover, it activates apoptosis via caspases 3 which in turn induces neurodegeneration and neuronal cell death (Figure 4) (Lehmann et al., 2012). Overexpression of let-7c in neurons also led to morphological and synaptic alterations, marked reduction in neuronal excitability through the inhibition of MeCP2 (McGowan et al., 2018), and decreased expression of the IGF-1R, which is expressed throughout the brain (Figure 4) (Liu et al., 2018).

Furthermore, IGF-1R/Insulin alterations are characteristic in patients with AD, Parkinson’s, and other neurodegenerative disorders. IGF-1 is an essential factor for healthy
growth and development, involved in neuronal survival, myelin synthesis, cell metabolism, astrocyte function, angiogenesis, neuronal excitability, and oligodendrogeneration (Figure 4) (Bassil et al., 2014). Also, a decrease in IGF-1 has been reported in people with DS (Anneren et al., 1990; Barreca et al., 1994; Torrado et al., 1991). Moreover, overexpression of let-7c in the brain of DS adults with dementia was observed, demonstrating its involvement with this process (Tili et al., 2018). Let-7c overexpression is also related to mitochondrial cardiomyopathies. In trisomic hearts, down-regulation was observed of the SLC25A4/ANT1 gene (Solute carrier family 25 member 4/ Adenine nucleotide translocator 1, OMIM #103220), a predicted target of let-7c and associated with mitochondrial and cardiac anomalies(Izzo et al., 2017). Besides, mitochondrial dysfunction is closely linked to the increase in oxidative stress, which plays a central role in the pathogenesis of DS and the etiology of different intellectual disabilities, as it affects highly oxidative tissues such as the brain, suggesting a synergism between let-7c and oxidative stress (Esbensen, 2010; Perluigi & Butterfield, 2012; Valenti et al., 2014; Wallace & Fan, 2010).

Regarding circulating miR-155 expression, we do not observe significance in the DS people studied. Previous studies using post-mortem brain tissue of 34-42-year-old donors with DS and dementia found a significant up-regulation of this miRNA (Tili et al., 2018). Interestingly, in the DS mouse model Ts65Dn, miR-155 showed significant over-expression in the hippocampus and whole blood, but not in lung tissue. Also, there was a down-regulation of the mRNA target Ship1 (inositol phosphatase) in the Ts65Dn hippocampus, but not in lung (Bofill-De Ros et al., 2015). The previous evidence and our results suggest that physiopathological changes in miR-155 expression may be tissue and temporally specific. In-depth follow-up studies are necessary to analyze these changes in the brain tissue to understand its contribution to neurodegeneration in DS.

The role in the development and adult central nervous system (CNS) of several miR-155 gene targets has been demonstrated in murine and cellular models (Keck-Wherley et al., 2011; Tili et al., 2018). miR-155 predicted gene target pathways are highly enriched for adhesion molecules such as Pcdhs, which are type I transmembrane receptors expressed predominantly in the central nervous system (CNS) and located in part in synapses involved in pivotal developmental processes, such as axon guidance and dendrite arborization. Changes in their expression might play a role in DS, as has been demonstrated for other neurodevelopmental disorders such as autism, encephalopathy epilepsy, Fragile X syndrome, and neurodegenerative diseases (Keeler et al., 2015; Kim et al., 2015; Yan et al., 2014).

Notably, our results showed a negative correlation between miR-155 expression and HDL-cholesterol levels. miR-155 is a multi-functional miRNA implicated in several pathological processes such as hematopoietic lineage differentiation, immunity, inflammation, cardiovascular function, and neurodegeneration. It has a significant role as a component of inflammatory signal transduction in the pathogenesis of atherosclerosis due to its expression in endothelial cells, macrophages, dendritic cells, vascular smooth muscle cells (VSMCs), and differentiation of leukocyte subsets (Ma et al., 2013). Human in vivo studies have shown that miR-155 is up-regulated in atherosclerotic lesions while, its circulating levels are reduced (Ma et al., 2013). Also, animal models have shown enhanced atherosclerosis in LDL-R−/− mice (Donners et al., 2012) and reduced atherosclerosis in Apoe−/− mice (Kuziel et al., 2003). It was additionally found that miR-155 targets LDL receptors, down-regulating lipid uptake. These findings suggest that up-regulation of miR-155 contributes to high circulating LDL levels. Nevertheless, there is no direct evidence for mechanisms that relate miR-155 expression with HDL levels. HDL is the only form of cholesterol in the brain, is rich in the apolipoprotein ApoE, and contributes to Aβ peptide clearance. ApoE is present in circulating LDL-C and functions as its ligand for cellular lipid uptake. There are three isoforms for ApoE, ApoE2-4, from which ApoE4 is associated with higher serum levels of triglycerides and LDL-C contributing to atherosclerosis. Nevertheless, in the brain, ApoE4-HDL is less effective in the clearance of Aβ peptide than ApoE2/3-HDL (Kuziel et al., 2003).

To understand the mechanism that links miR-155 mRNA targets to HDL-C levels, we performed a deeper in silico analysis, which showed that it might modulate molecules such as the aryl hydrocarbon receptor nuclear translocator like (ARNTL, OMIM #602550), also known as Brain and Muscle ARNT-Like 1 (BMAL1, OMIM #602550). ARNTL encodes a BHLH transcription factor, which plays a role in the cellular response to lipid, fat cell differentiation, and the pathway of the regulation of lipid metabolism by PPARalpha (Table 4). Lee et al., 2012 showed that the CLOCK/BMAL1 complex act up-regulating human LDLR promoter activity, suggesting a role for this gene in cholesterol homeostasis (Lee et al., 2012). Moreover, this gene is also responsible for the regulation of glucose homeostasis and metabolism, which can lead to hypo-insulinemia or diabetes when disrupted (Marcheva et al., 2010). Altogether, these observations reinforce the possible link of miR-155 targets with lipid metabolism observed in DS patients (Figure 4).

Down syndrome associated-neurodegeneration such as Alzheimer's disease, is a multifactorial puzzle linked to an altered genetic background, including alterations
in miRNA expression, but potentiated by dyslipidemias (Mahley, 2016; Real de Asua et al., 2014; Tokuda et al., 2000). Elevated cholesterol levels induce accelerated APP processing in its amyloidogenic pathway, a condition related to the development of Alzheimer's dementia (Bodovitz & Klein, 1996; Burns et al., 2003; Buxbaum et al., 2001; Simons et al., 1998). Studies of the lipid profile in children with DS, compared with their euploid siblings, adjusting for BMI showed that even in normal body weight, the DS children presented alterations in cholesterol, triglycerides, HDL, and LDL (Adelekan et al., 2012; de la Piedra et al., 2017). Our results demonstrate that individuals with DS have alterations in the lipid profile compared to controls at an early age as an increase in cholesterol, triglycerides, and low levels of HDL; and consistent in adults with DS. These results support the idea that the alterations in lipid metabolism are not only due to obesity but possibly to the presence of an extra copy of chromosome 21, thus constituting a risk factor for AD neurodegeneration. Several reports have determined a positive correlation of Aβ levels with elevated cholesterol and low HDL levels (Ehehalt et al., 2003; Tokuda et al., 2000; Wahrle et al., 2004). HDL maintains the transport of cholesterol to neurons for functioning and has a role in Aβ clearance; hence, high cholesterol levels and low HDL levels are related to cognitive disorders (Figure 4) (Ehehalt et al., 2003; He et al., 2016; Tokuda et al., 2000; Wahrle et al., 2004). In line with this evidence, we found that let-7c overexpression was higher among DS individuals with low-HDL levels. Still, we did not find significative correlation between let-7c and HDL or mRNA targets related to lipid metabolism by in-silico analysis. Since HDL particles transport miRNAs (Baldan & de Aguiar Vallim, 2016), it may be possible that HDL plays a role in proinflammatory let-7c clearance altogether amyloid peptides elimination. Also, we found that miR-155 levels negatively correlate to low HDL levels in the DS population. Even though no mRNA targets for miR-155 involved in lipid metabolism have been demonstrated, based on our in-silico analysis, a direct relationship between its expression and lipid profile alterations is likely. However, the fact that there is a negative correlation of miR-155 expression with HDL level or a differential expression of let-7c according to lipid levels suggests the existence of a complex molecular network linking both parameters.

Overall, our results suggest that a set of differentially expressed miRNAs promotes the progression of cognitive impairment in patients with DS by regulating genes of biological pathways involved in lipid metabolism and nervous system development. Moreover, other biological processes such as inflammation and the immune system must integrate for Alzheimer’s neurodegeneration in the DS puzzle (Figure 4).

5 Conclusion

Our results reveal an up-regulated expression pattern for circulating let-7c miRNA and an inverse correlation between miR-155 expression and low HDL-C levels. The data suggests that in Down syndrome, the chromosome 21-encoded let-7c and miR-155 may be dysregulated and, together with dyslipidemia, may play a role in the homeostasis of molecules related to cognitive function and early development of Alzheimer’s disease dementia. This implies that modulating the expression of these miRNAs in the CNS may help abrogate the inevitable pathway to dementia in adults with Down syndrome.

Ethical Compliance

The study followed the Declaration of Helsinki and Good Clinical Practice guidelines provisions and was approved by the Research Ethics Committee at the Medical School of the Autonomous University of Sinaloa, which has a national certification (CONBIOÉTICA-25-CEI-003-20181012). Parents or legal guardians of people with DS were informed before the evaluation and provided written consent to undergo study procedures.

Acknowledgments

KAP acknowledges CABANA program for training in bioinformatics. Technical support for this work was obtained from Luis Alberto Aguilar Bautista, Alejandro de León Cuevas, Carlos Sair Flores Bautista, and Jair García of the Laboratorio Nacional de Visualización Científica Avanzada (LAVIS).

Conflict of Interest

The author declares no conflict of interest.

Author Contributions

Pérez-Villarreal JM and Aviña-Padilla K contributed to the study design, performing experiments, collection, analysis and interpretation of data, and drafting the paper. Beltrán-López E, Guadrón-Llanos AM, and López-Bayghen E assisted with technical support, patient data collection, ideas, and critical analysis, and interpretation of data. Meraz-Ríos MA and Varela-Echevarria A contributed to the writing, reviewing, and discussion of the manuscript. Magaña-Gómez J and Angulo-Rojo C made a substantial contribution to conception and design of the project, analysis and interpretation of data, and writing and revising the paper to the final version to be published. Angulo-Rojo C was responsible for the funding support and the general supervision of the research.
DATA AVAILABILITY STATEMENT
Data are available on request from the authors.

ORCID
Alma Marlene Guadrón-Llanos https://orcid.org/0000-0003-4782-6398
Carla Angulo-Rojo https://orcid.org/0000-0002-5097-2444

REFERENCES
Abd-El-Fattah, A. A., Sadik, N. A., Shaker, O. G., & Aboulftouh, M. L. (2013). Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell Biochemistry and Biophysics, 67, 875–884.

Adelekan, T., Magge, S., Shults, J., Stallings, V., & Stettler, N. (2012). Lipid profiles of children with down syndrome compared with their siblings. Pediatrics, 129, e1382–e1387.

Agarwal, V., Bell, G. W., Nam, J.- W., & Bartel, D. P. (2015). Predicting effective microRNA target sites in mammalian mRNAs. eLife, 4, e05005.

Allison, D. B., Gomez, J. E., Heshka, S., Babbitt, R. L., Geliebter, A., Kreibich, K., & Heymsfield, S. B. (1995). Decreased resting metabolic rate among persons with down syndrome. International Journal of Obesity and Related Metabolic Disorders, 19, 858–861.

Anneren, G., Gustafsson, J., Sara, V., & Tuvemo, T. (1993). Normalized growth velocity in children with Down’s syndrome during growth hormone therapy. Journal of Intellectual Disability Research, 37, 381–387.

Anneren, G., Gustavson, K. H., Sara, V. R., & Tuvemo, T. (1990). Growth retardation in down syndrome in relation to insulin-like growth factors and growth hormone. American Journal of Medical Genetics. Supplement, 7, 59–62.

Antonarakis, S. E. (2017). Down syndrome and the complexity of genome dosage imbalance. Nature Reviews. Genetics, 18, 147–163.

Antonarakis, S. E., Lyle, R., Dermitzakis, E. T., Reymond, A., & Deutsch, S. (2004). Chromosome 21 and down syndrome: From genomics to pathophysiology. Nature Reviews. Genetics, 5, 725–738.

Asim, A., Kumar, A., Muthuswamy, S., Jain, S., & Agarwal, S. (2015). Down syndrome: An insight of the disease. Journal of Biomedical Science, 22, 41.

Balda, A., & de Agüiar Vallim, T. Q. (2016). miRNAs and high-density lipoprotein metabolism. Biochimica et Biophysica Acta, 1861, 2053–2061.

Ballard, C., Mobley, W., Hardy, J., Williams, G., & Corbett, A. (2016). Dementia in Down’s syndrome. The Lancet Neurology, 15, 622–636.

Barreca, A., Rasore Quartino, A., Acutis, M. S., Ponzani, P., Damonte, G., Miani, E., Balestra, V., Giordano, G., & Minuto, F. (1994). Assessment of growth hormone insulin like growth factor-1 axis in Down’s syndrome. Journal of Endocrinological Investigation, 17, 431–436.

Basil, J. S., Santoro, S. L., Martin, L. J., Healy, K. W., Chini, B. A., & Saal, H. M. (2016). Retrospective study of obesity in children with down syndrome. The Journal of Pediatrics, 173, 143–148.

Bassil, F., Fernagut, P.-O., Bezard, E., & Meissner, W. G. (2014). Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification? Progress in Neurobiology, 118, 1–18.

Bertapelli, F., Pitetti, K., Agiovlasitis, S., & Guerra-Junior, G. (2016). Overweight and obesity in children and adolescents with down syndrome-prevalence, determinants, consequences, and interventions: A literature review. Research in Developmental Disabilities, 57, 181–192.

Bodovitz, S., & Klein, W. L. (1996). Cholesterol modulates-secretase cleavage of amyloid precursor protein. Journal of Biological Chemistry, 271, 4436–4440.

Bofill-De Ros, X., Santos, M., Vila-Casadesus, M., Villanueva, E., Andreu, N., Dierssen, M., & Fillat, C. (2015). Genome-wide miR-155 and miR-802 target gene identification in the hippocampus of Ts65Dn down syndrome mouse model by miRNA sponges. BMC Genomics, 16, 907.

Buonomo, P. S., Bartuli, A., Mastrogiorgio, G., Vittucci, A., Di Camillo, C., Bianchi, S., Pires Marafon, D., Villani, A., & Valentinii, D. (2016). Lipid profiles in a large cohort of Italian children with down syndrome. European Journal of Medical Genetics, 59, 392–395.

Burns, M., Gaynor, K., Olm, V., Mercken, M., LaFrancois, J., Wang, L., Mathews, P. M., Noble, W., Matsuoka, Y., & Duff, K. (2003). Presenilin redistribution associated with aberrant cholesterol transport enhances β-amyloid production in vivo. Journal of Neuroscience, 23, 5645–5649.

Buxbaum, J. D., Geogaghan, N. S., & Friedhoff, L. T. (2001). Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Ap peptide. Journal of Alzheimer’s Disease, 3, 221–229.

Chen, J., Qi, Y., Liu, C. F., Lu, J. M., Shi, J., & Shi, Y. (2018). MicroRNA expression data analysis to identify key miRNAs associated with Alzheimer’s disease. The Journal of Gene Medicine, 20, e3014.

Chen, Y., & Wang, X. (2019). miRDB: An online database for prediction of functional microRNA targets. Nucleic Acids Research, 48, D127–D131.

de Graaf, G., Buckley, F., & Skotlo, B. G. (2017). Estimation of the number of people with down syndrome in the United States. Genetics in Medicine, 19, 439–447.

de la Piedra, M. J., Alberti, G., Cárdenas, A., Paul, M. A., & Lizama, M. (2017). Alta frecuencia de dislipidemias en niños y adolescentes con Síndrome de Down. Revista Chilena de Pediatría, 88, 595–601.

Donners, M. M., Wols, I. M., Stoger, L. J., van der Vorst, E. P., Pottgens, C. C., Heymans, S., Schroen, B., Gijbels, M. J., & de Winther, M. P. (2012). Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PLoS One, 7, e35877.

Ehehalt, R., Keller, P., Haass, C., Thiele, C., & Simons, K. (2003). Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. The Journal of Cell Biology, 160, 113–123.

Elton, T. S., Sansom, S. E., & Martin, M. M. (2010). Trisomy-21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteins. RNA Biology, 7, 540–547.

Esbensen, A. J. (2010). Health conditions associated with aging and end of life of adults with down syndrome. International Review of Research in Mental Retardation, 39, 107–126.

Friedewald, W. T., Levy, L. R., & Fredrickson, D. S. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in
plasma, without use of the preparative ultracentrifuge. Clinical Chemistry, 18, 499–502.

Friedman, R. C., Farh, K. K., Burge, C. B., & Bartel, D. P. (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genome Research, 19, 20–22.

Grammatikopoulou, M. G., Manai, A., Tsigga, M., Tsiligiropoulos-Fachantidou, A., Galli-Tsinos, A., & Zakas, A. (2008). Nutrient intake and anthropology in children and adolescents with down syndrome—a preliminary study. Developmental Neurorehabilitation, 11, 260–267.

He, Q., Li, Q., Zhao, J., Wu, T., Ji, L., Huang, G., & Ma, F. (2016). Relationship between plasma lipids and mild cognitive impairment in the elderly Chinese: A case-control study. Lipoins in Health and Disease, 15, 146.

Izzo, A., Manco, R., de Cristofaro, T., Bonfiglio, F., Cicatiello, R., Mollo, N., De Martino, M., Genesio, R., Zannini, M., Conti, A., & Nitsch, L. (2017). Overexpression of chromosome 21 miRNAs may affect mitochondrial function in the hearts of down syndrome fetuses. International Journal of Genomics, 2017, 8737649.

Keck-Wherley, J., Grover, D., Bhattacharyya, S., Xu, X., Holman, D., Lombardini, E. D., Verma, R., Biswas, R., & Galdizck, Z. (2011). Abnormal microRNA expression in T susceptible and whole blood: Contributions to down syndrome phenotypes. Developmental Neuroscience, 33, 451–467.

Keeler, A. B., Molumby, M. J., & Weiner, J. A. (2015). Protocadherins branch out: Multiple roles in dendrite development. Cell Adhesion & Migration, 9, 214–226.

Kim, J., Yoon, H., Horiie, T., Burchett, J. M., Restivo, J. L., Riolan, N., Ramirez, C. M., Verghese, P. B., Ihara, M., & Hoe, H.-S. (2015). microRNA-33 regulates ApoE lipopification and amyloid-β metabolism in the brain. Journal of Neuroscience, 35, 14717–14726.

Korenberg, J. R., Chen, X. N., Schipper, R., Sun, Z., Gonsky, R., Gerwehr, S., Carpenter, N., Daumer, C., Dignan, P., Disteste, C., Dignan, P., & Disteste, C. (1994). Down syndrome phenotypes: The consequences of chromosomal imbalance. Proceedings of the National Academy of Sciences of the United States of America, 91, 4997–5001.

Kumar, V., Kumar, V., Chaudhary, A. K., Coulter, D. W., McGuire, T., & Mahato, R. I. (2018). Impact of miRNA-mRNA profiling and their correlation on medulloblastoma tumorigenesis. Molecular Therapy-Nucleic Acids, 12, 490–503.

Kuo, Y.-M., Emmerling, M. R., Bisgaier, C. L., Essenburg, A. D., Lampert, H. C., Drumm, D., & Roher, A. E. (1998). Elevated low-density lipoprotein in Alzheimer's disease correlates with brain ApoE 1–42 levels. Biochemical and Biophysical Research Communications, 252, 711–715.

Kuziel, W. A., Dawson, T. C., Quinones, M., Garvito, E., Chenaux, G., Ahuja, S. S., Reddick, R. L., & Maeda, N. (2003). CCR5 deficiency is not protective in the early stages of atherogenesis in brain Aβ1–42 levels. Circulation Research, 93, 252–258.

Lee, Y. J., Han, D. H., Pak, Y. K., & Cho, S. H. (2012). Circadian regulation of low density lipoprotein receptor promoter activity by CLOCK/BMAL1, Hes1 and Hes6. Experimental & Molecular Medicine, 44, 642–652.

Lehmann, S. M., Kruger, C., Park, B., Derkow, K., Rosenberger, K., Baumgart, J., Trimbach, T., Eom, G., Hinz, M., Kaul, D., Habbel, P., Kalin, R., Franzen, E., Rybak, A., Nguyen, D., Veh, R., Ninnemann, O., Peters, O., Nitsch, R., ... Lehndt, S. (2012).

An unconventional role for miRNA: Let-7 activates toll-like receptor 7 and causes neurodegeneration. Nature Neuroscience, 15, 827–835.

Liu, G. X., Ma, S., Li, Y., Yu, Y., Zhou, Y. X., Lu, Y. D., Jin, L., Wang, Z. L., & Yu, J. H. (2018). Hsa-let-7c controls the committed differentiation of IGF-1-treated mesenchymal stem cells derived from dental pulps by targeting IGF-1R via the MAPK pathways. Experimental & Molecular Medicine, 50, 25.

Luke, A., Roizen, N. J., Sutton, M., & Schoeller, D. A. (1994). Energy expenditure in children with down syndrome: Correcting metabolic rate for movement. The Journal of Pediatrics, 125, 829–838.

Ma, X., Ma, C., & Zheng, X. (2013). MicroRNA-155 in the pathogenesis of atherosclerosis: A conflicting role? Heart, Lung & Circulation, 22, 811–818.

Mahley, R. W. (2016). Central nervous system lipoproteins: ApoE and regulation of cholesterol metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 36, 1305–1315.

Marcheva, B., Ramsey, K. M., Buhr, E. D., Kobayashi, Y., Su, H., Ko, C. H., Ivanova, G., Omura, C., Mo, S., Vitaterma, M. H., Lopez, J. P., Phillipson, L. H., Bradfield, C. A., Crosby, S. D., JeBailey, L., Wang, X., Takahashi, J. S., & Bass, J. (2010). Disruption of the CLOCK components CLOCK and BMAL1 leads to hypoinsulinemia and diabetes. Nature, 466, 627–631.

McGowan, H., Mirabella, V. R., Hamod, A., Karakhanayan, A., Mlynaryk, N., Moore, J. C., Tischfield, J. A., Hart, R. P., & Pang, Z. P. (2018). Hsa-let-7c miRNA regulates synaptic and neuronal function in human neurons. Frontiers in Synaptic Neuroscience, 10, 19.

Melville, C. A., Cooper, S.-A., McGrother, C. W., Thorp, C. F., & Collacott, R. (2005). Obesity in adults with down syndrome: A case–control study. Journal of Intellectual Disability Research, 49, 125–133.

NHI, & NHLBI. (2001). ATP III guidelines at-a-glance quick reference, in: Public health service (ed.) (p. 10). U.S. Department of Health and Human Services.

Perluigi, M., Butterfield, D.A., 2012. Oxidative stress and down syndrome: A route toward Alzheimer-like dementia. Current Gerontology and Geriatrics Research, 2012, 724904, 1, 10.

Pfaff, M. W. (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research, 29, e55.

Real de Asua, D., Parra, P., Costa, R., Moldenhauer, F., & Suarez, C. (2014). Evaluation of the impact of abdominal obesity on glucose and lipid metabolism disorders in adults with down syndrome. Research in Developmental Disabilities, 35, 2942–2949.

Robert, J., Button, E. B., Yuen, B., Gilmore, M., Kang, K., Bahrami, A., Stukas, S., Zhao, W., Kucic, I., & Wellington, C. L. (2017). Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels. eLife, 6, e29595.

Rubenstein, E., Hartley, S., & Bishop, L. (2020). Epidemiology of dementia and Alzheimer disease in individuals with down syndrome. JAMA Neurology, 77, 262–264.

Ruljter, J. M., Ramakers, C., Hoogaars, W. M., Karlen, Y., Bakker, O., van den Hoff, M. J., & Moorman, A. F. (2009). Amplification efficiency: Linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Research, 37, e45.

Saghasadeh, A., Mahmoudi, M., Dehghani Ashkezari, A., Oliaie Rezaie, N., & Rezaei, N. (2017). Systematic review and meta-analysis shows a specific micronutrient profile in people with...
down syndrome: Lower blood calcium, selenium and zinc, higher red blood cell copper and zinc, and higher salivary calcium and sodium. PLoS One, 12, e0175437.

Scheltens, P., Blennow, K., Breteler, M. M., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016). Alzheimer’s disease. Lancet, 388, 505–517.

Shahabi, N. S., Fakhraee, H., Kazemian, M., Afjeh, A., Fallahi, M., Shariati, M., & Gorji, F. (2017). Frequency and causes of hypotonia in neonatal period with the gestational age of more than 36 weeks in NICU of Mofid children hospital, Tehran, Iran during 2012-2014. Iranian Journal of Child Neurology, 11, 43–49.

Sierra Romero, M. D. C., Navarrete Hernandez, E., Canun Serrano, S., Reyes Pablo, A. E., & Valdes Hernandez, J. (2014). Prevalence of down syndrome using certificates of live births and fetal deaths in Mexico 2008-2011. Boletín Médico del Hospital Infantil de México, 71, 292–297.

Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C. G., & Simons, K. (1998). Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proceedings of the National Academy of Sciences, 95, 6460–6464.

Tenneti, N., Dayal, D., Sharda, S., Panigrahi, I., Didi, M., Attri, S. V., Sachdeva, N., & Bhalla, A. K. (2017). Concentrations of leptin, adiponectin and other metabolic parameters in non-obese children with down syndrome. Journal of Pediatric Endocrinology & Metabolism, 30, 831–837.

Tili, E., Mezache, L., Michaille, J. J., Amann, V., Williams, J., Vandiver, P., Quinonez, M., Fadda, P., Mikhail, A., & Nuovo, G. (2018). microRNA 155 up regulation in the CNS is strongly correlated to Down’s syndrome dementia. Annals of Diagnostic Pathology, 34, 103–109.

Tokuda, T., Calero, M., Matsubara, E., Vidal, R., Kumar, A., Permanne, B., Zlokovic, B., Smith, J. D., Ladu, M. J., & Rostagno, A. (2000). Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer’s amyloid β peptides. Biochemical Journal, 348, 359–365.

Torrado, C., Bastian, W., Wisniewski, K. E., & Castells, S. (1991). Treatment of children with down syndrome and growth retardation with recombinant human growth hormone. The Journal of Pediatrics, 119, 478–483.

Tsou, A. Y., Bulova, P., Capone, G., Chicoine, B., Gelaro, B., Harville, T. O., Martin, B. A., McGuire, D. E., McKelvey, K. D., Peterson, M., Tyler, C., Wells, M., Whitten, M. S., & Global Down Syndrome Foundation Medical Care Guidelinesfor Adults with Down Syndrome, W. (2020). Medical Care of Adults with down Syndrome: A clinical guideline. JAMA, 324, 1543–1556.

Valenti, D., de Bari, L., De Filippis, B., Henrion-Cauda, A., & Vacca, R. A. (2014). Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: An overview of down syndrome, autism, fragile X and Rett syndrome. Neuroscience and Biobehavioral Reviews, 46(Pt 2), 202–217.

Wahrle, S. E., Jiang, H., Farsadanian, M., Legleiter, J., Han, X., Fryer, J. D., Kowalewski, T., & Holtzman, D. M. (2004). ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. Journal of Biological Chemistry, 279, 40987–40993.

Wallace, D. C., & Fan, W. (2010). Energetics, epigenetics, mitochondrial genetics. Mitochondrion, 10, 12–31.

Weber, J. A., Baxter, D. H., Zhang, S., Huang, D. Y., Huang, K. H., Lee, M. J., Galas, D. J., & Wang, K. (2010). The microRNA spectrum in 12 body fluids. Clinical Chemistry, 56, 1733–1741.

Xu, Y., Li, W., Liu, X., Chen, H., Tan, K., Chen, Y., Tu, Z., & Dai, Y. (2013). Identification of dysregulated microRNAs in lymphocytes from children with down syndrome. Gene, 530, 278–286.

Yan, X., Lukas, J., Lin, J., Ernst, M., Koczan, D., Witt, M., Fuellen, G., Wree, A., Rolfs, A., & Luo, J. (2014). Aberrant expressions of delta-protocadherins in the brain of Npc1 mutant mice. Histology and Histopathology, 29, 1185–1199.

Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C., & Chanda, S. K. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nature Communications, 10, 1523.

Zimmet, P., Alberti, K. G. M., Kaufman, F., Tajima, N., Silink, M., Arslanian, S., Wong, G., Bennett, P., Shaw, J., & Caprio, S. (2007). The metabolic syndrome in children and adolescents—an IDF consensus report. Pediatric Diabetes, 8, 299–306.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Pérez-Villarreal, J. M., Aviña-Padilla, K., Beltrán-López, E., Guadrón-Llanos, A. M., López-Bayghen, E., Magaña-Gómez, J., Meraz-Rios, M. A., Varela-Echavarriá, A. & Angulo-Rojo, C. (2022). Profiling of circulating chromosome 21-encoded microRNAs, miR-155, and let-7c, in down syndrome. Molecular Genetics & Genomic Medicine, 10, e1938. https://doi.org/10.1002/mgg3.1938